Tianjin TEDA Biomedical Engineering Company Limited released its Monthly Return for the period ended 30 June 2026, confirming that both authorised and issued share capital remained unchanged during the month.

The issuer’s authorised share capital was steady at 1,436.40 million H shares and 697.50 million domestic shares, each with a par value of RMB 0.10, translating to total authorised capital of RMB 213.39 million.

Issued share figures were equally unchanged. Outstanding H shares stood at 1,436.40 million, while domestic shares totalled 697.50 million. No treasury shares were recorded, and there were no increases, decreases, repurchases or cancellations across any share classes.

The company confirmed full compliance with Hong Kong’s minimum 25% public-float requirement for its H shares. Throughout June, TEDA Biomedical executed no share option grants, warrant issues, convertible securities, or other equity-linked arrangements.

All statutory confirmations required under Hong Kong Listing Rules—covering authorisations, regulatory filings, and identical rights among issued shares—were provided by Director and Company Secretary Sun Li in the submission dated 3 July 2026.

The report underscores operational steadiness in TEDA Biomedical’s capital structure, with no equity dilution or treasury share activity recorded during the month.